Antikoagulační terapie u fibrilace síní

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Anticoagulant therapy in atrial fibrillation
Authors

ŠPINAR Jindřich LÁBROVÁ Růžena

Year of publication 2011
Type Article in Periodical
Magazine / Source Remedia
MU Faculty or unit

Faculty of Medicine

Citation
Field Cardiovascular diseases incl. cardiosurgery
Keywords atrial fibrillation; warfarin; dabigatran; apixaban
Description The trials with drugs intended to replace warfarin in patients with atrial fibrillation have been named by the American Heart Association among the top ten discoveries of the year 2010. These are the following trials: RE-LY, ROCKET AF, and AVERROES. The RE-LY trial showed dabigatran to be superior to warfarin in 18,113 patients, with dabigatran at a dose of 110 mg being equally effective against cerebrovascular events (CVE) as warfarin and dabigatran at a dose of 150 mg reducing CVE and not increasing bleeding events. The ROCKET AF trial showed a downward trend in CVE and systemic embolization in 14,246 patients treated with rivaroxaban versus warfarin, without increased bleeding risk. The AVERROES trial proved apixaban to be superior to acetyl salicylic acid (ASA) in patients with atrial fibrillation who were ineligible for warfarin therapy. Further large clinical trials such as ARISTOTLE and ENGAGE are underway and the Czech Republic is among the participating countries.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.